Gantonoc, Gerve B.
HRN: 18-29-92 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/08/2024
CEFTRIAXONE 1G (VIAL)
08/08/2024
08/15/2024
IV
2g
Q25
Severe TBI Sec To MVA
Waiting Final Action
Indication: Prophylaxis Type of Infection: Skin & Soft TissueProphylaxis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes